Table 2.
Classification | Merit | Defect | |
---|---|---|---|
Live vaccine | Generally attenuated vaccine; Close to natural infection; Effectively stimulate immune system; Pathogen can reproduce in vivo; Low dosage; Long protection duration; No adjuvant needed |
Poor safety under natural conditions; Short shelf life; Not convenient storage and transportation |
|
Inactivated vaccine | Short development cycle; Safe to use; Easy to preserve | Cannot reproduce in vivo after immunization; Large immunize dosage; Short duration; Appropriate adjuvant is needed |
|
Gene engineering vaccine | Recombinant subunit vaccine | Excellent safety; Simple production; Easy control; High stability; High purity |
The expression is affected by the expression system; Weak immunogenicity; Short protection duration; Difficult to effectively remove intracellular pathogens |
DNA vaccine | High stability; Induce comprehensive immune response; Easy production in large scale; No risk of return of the virus; Low cost; The most promising vaccine |
Uncertain immune response caused by the vaccine; Tissue distribution and expression still unknown; More researches are needed to confirm the stability; Immune tolerance; Risk of integrating into the genome |
|
Gene deletion/mutant vaccine | High stability; Not easy to reverse under natural conditions; Good immunogenicity; Guaranteed safety; Important direction of vaccine development |
Not many successful cases; | |
Living-vector vaccine | Can be administered through mucous membrane system; Easy control; |
Restricted by its expression level and its persistence; Risk of plasmid loss reducing vaccine function; Environmental safety needs to consider |